Zacks Research Issues Positive Outlook for Exelixis Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for Exelixis in a report issued on Friday, February 6th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $0.65 per share for the quarter, up from their prior forecast of $0.61. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q2 2026 earnings at $0.68 EPS, FY2026 earnings at $2.91 EPS, Q1 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.97 EPS, Q4 2027 earnings at $1.12 EPS and FY2027 earnings at $3.84 EPS.

Other equities research analysts also recently issued reports about the company. Leerink Partners raised Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research report on Tuesday, October 21st. TD Cowen reaffirmed a “buy” rating on shares of Exelixis in a report on Wednesday, November 5th. Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Morgan Stanley upped their price objective on Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Finally, Oppenheimer reaffirmed a “market perform” rating and set a $36.00 target price on shares of Exelixis in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Exelixis presently has an average rating of “Hold” and an average target price of $46.16.

Exelixis Price Performance

Shares of Exelixis stock opened at $43.95 on Monday. The stock has a market cap of $11.78 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.74 and a beta of 0.42. The firm has a fifty day moving average price of $43.70 and a 200 day moving average price of $40.94. Exelixis has a 1 year low of $32.38 and a 1 year high of $49.62.

Institutional Investors Weigh In On Exelixis

Several large investors have recently bought and sold shares of EXEL. Richardson Financial Services Inc. lifted its position in shares of Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares in the last quarter. Anchor Investment Management LLC raised its stake in Exelixis by 500.0% in the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Root Financial Partners LLC acquired a new position in Exelixis in the 3rd quarter valued at $28,000. Luminist Capital LLC boosted its stake in Exelixis by 2,740.0% during the 2nd quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 685 shares during the last quarter. Finally, Activest Wealth Management purchased a new stake in shares of Exelixis during the fourth quarter worth $32,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 28,043 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the completion of the sale, the executive vice president owned 374,029 shares of the company’s stock, valued at approximately $15,926,154.82. The trade was a 6.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the transaction, the director directly owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. The trade was a 7.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 172,230 shares of company stock worth $7,401,923 in the last three months. 2.85% of the stock is owned by corporate insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.